ASPIBasic Materials · Specialty ChemicalsThe 3 Wall Street analysts covering ASP Isotopes, Inc. hold a median 12-month price target of $13 — +292.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 7 of 100 as at 11 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores ASP Isotopes, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (53): Smaller than most of the companies we track.
Issuance (5): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ASPI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +292.7% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 Apr 2026 | Canaccord Genuity | Maintains | Buy | $11 |
| 4 Dec 2025 | Cantor Fitzgerald | Initiates | Overweight | — |
| 24 Nov 2025 | Canaccord Genuity | Maintains | Buy | — |
| 17 Sept 2025 | Canaccord Genuity | Maintains | Buy | — |
| 21 May 2025 | Canaccord Genuity | Maintains | Buy | — |
| 18 Oct 2024 | Canaccord Genuity | Maintains | Buy | — |
| 4 Oct 2024 | Canaccord Genuity | Initiates | Buy | — |
| 7 Aug 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 17 Apr 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 29 Feb 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 5 Dec 2023 | HC Wainwright & Co. | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ASPI appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, ASP Isotopes, Inc. returned −61.7% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 84% of US stocks
Cheaper than 10% of US stocks
Cheaper than 50% of US stocks
Cheaper than 81% of US stocks
Higher than 97% of US stocks
Higher than 93% of US stocks
Higher than 32% of US stocks
Higher than 7% of US stocks
Higher than 76% of US stocks
Higher than 14% of US stocks
Higher than 21% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
ASP Isotopes, Inc. has a market value of $507.5M and an enterprise value of $532.2M.
Revenue in the twelve months to 30 June 2026: $30.9M. The latest quarter grew 327.6% year on year.
Net income over the same four quarters: −$117.3M, a −380.3% net margin.
Free cash flow in the twelve months to 30 June 2026: −$83.6M.
Trailing P/E: −1.6×; forward P/E: −2.9× — the forward figure prices analyst consensus estimates, not reported earnings.
ASP Isotopes, Inc. employs 271 people — $114K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own ASP Isotopes, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
ASP Isotopes Inc. held an Analyst/Investor Day, the proceedings of which were published as a transcript by Seeking Alpha. The item consists of the transcript of that event.
Why it matters — A watcher of ASPI would care because the transcript provides direct insights into the company's own presentations and analyst discussion.
ASP Isotopes held its inaugural Capital Markets Day in London on September 8, 2026, where management outlined the company's strategy across nuclear medicine, electronics, helium and LNG, and nuclear fuels, and reviewed the building blocks supporting its long-term growth potential.
Why it matters — ASPI watchers would care because the event provides management's detailed strategic overview and growth outlook for the company's diversified critical materials businesses.
ASP Isotopes CEO Paul Mann said during a conference presentation that several business units, including helium, liquefied natural gas, stable isotopes, and radiopharmaceuticals, are expected to enter commercial production or expand output over the next six months.
Why it matters — ASPI watchers would care because the company's near-term production milestones signal progress across its helium and stable isotope growth initiatives.
ASP Isotopes Inc. announced that Tetra4, a subsidiary of Renergen and developer of the Virginia Gas Project, has started commissioning its Phase 1 liquid helium plant in South Africa following engineering optimization. The company expects to deliver liquid helium to customers in September, ramp to nameplate capacity during the second half, and potentially advance to Phase 2 during 2H 2026.
Why it matters — The commissioning marks a key operational milestone for ASP Isotopes' helium production, potentially adding one of the first new liquid helium supplies to enter the market during a global shortage.
ASP Isotopes announced that its wholly-owned subsidiary, Quantum Leap Energy, is evaluating metal conversion opportunities in Namibia. As part of this evaluation, a public environmental and social impact assessment has begun for a proposed pilot-scale hydrofluorination and fluorination facility in the Walvis Bay area.
Why it matters — This indicates ASPI's subsidiary is exploring expansion of its nuclear fuel cycle activities into a new geographic region, which could broaden its operational footprint.
The 3 Wall Street analysts covering ASP Isotopes, Inc. have a median 12-month price target of $13, with estimates ranging from $11 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering ASP Isotopes, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks ASP Isotopes, Inc. 7 out of 100 across roughly 4,600 US stocks as at 11 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 11 Sept 2026, ASP Isotopes, Inc. ranks 7 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (53 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies +292.7% from the last close, and Ticker Nerd's factor model ranks ASP Isotopes, Inc. 7 out of 100 as at 11 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering ASP Isotopes, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ASPI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $15 over the next 12 months.
ASP Isotopes, Inc. returned -61.7% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
ASP Isotopes Inc. is an advanced materials company focused on developing isotope enrichment technologies for specialized markets.
The most recent item we track (Seeking Alpha, 9 Sept 2026): "ASP Isotopes Inc. (ASPI) Analyst/Investor Day Transcript". ASP Isotopes Inc. held an Analyst/Investor Day, the proceedings of which were published as a transcript by Seeking Alpha. The item consists of the transcript of that event.
ASP Isotopes Inc. is an advanced materials company focused on developing isotope enrichment technologies for specialized markets. The company works on producing and commercializing isotopes used in nuclear medicine, semiconductors, advanced nuclear fuels, and other industrial applications. Its current business is organized around Nuclear Fuels, Specialist Isotopes and Related Services, and Helium and LNG. The Nuclear Fuels segment is centered on technologies for high-assay low-enriched uranium and lithium-6, while the Specialist Isotopes segment targets high-value, low-volume isotopes such as carbon-14, molybdenum-100, and silicon-28. ASP Isotopes Inc. also develops related enrichment and separation processes designed to support critical materials supply chains across healthcare, energy, and technology industries. Founded in 2021 and headquartered in Dallas, Texas, ASP Isotopes Inc. is positioned as a supplier of specialized isotope products and services in niche global markets.
CEO Mr. Paul Elliot Mann C.F.A. · 271 employees · United States · https://aspisotopes.com
